AsiDNA™ Letter - No. 2

Role of AsiDNA™ in the new combination strategies

Ladies, Gentlemen and shareholders

The complexity and diversity of cancers require multiple therapeutic approaches. The combination of several anti-cancer agents has become the norm in oncology, especially to treat the very aggressive or resistant cancers.

Thanks to its original anti-tumor activity and its good tolerance already clinically demonstrated, AsiDNA™ is ideally positioned to play a key role in new combination strategies aiming to treat these cancers, for which the medical needs remain significant.

>Read the Letter

Attachments

  • Original document
  • Permalink

Disclaimer

Onxeo SA published this content on 18 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 July 2019 16:44:02 UTC